サンプル依頼リスト カート
  • English
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1722409

眼科用剤市場レポート：タイプ別、薬剤クラス別、適応症別、剤形別、流通チャネル別、地域別、2025年～2033年

Ophthalmic Drugs Market Report by Type, Drug Class, Indication, Dosage Form, Distribution Channel, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 150 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.08円
眼科用剤市場レポート：タイプ別、薬剤クラス別、適応症別、剤形別、流通チャネル別、地域別、2025年～2033年
出版日: 2025年05月01日
発行: IMARC
ページ情報: 英文 150 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の眼科用剤の市場規模は2024年に472億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに712億米ドルに達し、2025年から2033年にかけて4.44%の成長率（CAGR）を示すと予測しています。同市場は、眼疾患と診断される患者数の増加、ドラッグデリバリーシステムの大幅な技術進歩、有利な政府の取り組みと資金援助、老年人口の増加、糖尿病に罹患する患者数の増加によって推進されています。

眼科用剤市場分析：

主な市場促進要因：目に関する問題の高まり、薬剤製剤の著しい発展、技術・製薬研究分野への旺盛な投資が、眼科用剤の成長を促進する主な市場促進要因の一部です。

主な市場動向：併用療法を選択する個人の増加、業界プレイヤー間の戦略的パートナーシップの増加、以前は治療不可能と考えられていた症状の治療法開発に重点が置かれるようになったことなどが、眼科用剤市場の動向の一部です。

地理的動向：北米は強力なヘルスケア・インフラと糖尿病関連眼疾患の診断件数の増加により市場をリードしています。高齢化が進み、研究開発（R&D）が活発化している欧州が第2位の市場です。

競合情勢：AbbVie Inc.、Aerie Pharmaceuticals Inc.、Akorn Inc.、Alcon、Bausch Health Companies Inc.、Bayer AG、F. Hoffmann-La Roche AG、Johnson &Johnson、Merck &Co.Inc.、ノバルティスAG、リジェネロン・ファーマシューティカルズInc.Ltd.、Sun Pharmaceutical Industries Ltd.などが眼科用剤業界の主要プレーヤーです。

課題と機会：この市場の課題には、医薬品承認の遅れにつながる厳しい規制環境や、開発された眼科用剤のコスト上昇などがあります。さらに、眼科用剤市場の直近の機会としては、医療アクセスの増加に伴う新興市場の可能性が挙げられます。

眼科用剤市場の動向：

眼疾患の有病率の上昇

眼に関連する問題が世界的に増加していることが、眼科用剤の需要を大きく高めています。データによると、白内障、緑内障、加齢黄斑変性症（AMD）、糖尿病性網膜症などの病気が市場を牽引しています。世界保健機関（WHO）によると、毎年少なくとも22億人が遠方視力障害を抱えています。また、これらの視力障害のうち最低10億件は回避できたか、まだ予防できていないとしています。眼疾患の患者数の増加は、抗緑内障薬、抗VEGF薬、抗炎症薬などの治療薬の需要増加に大きくつながっています。この相関関係は、有望な先進治療ソリューションを描き、眼科用剤市場の最近の研究開発を促進する数多くの市場調査報告書によって裏付けられています。

ドラッグデリバリーシステムの著しい技術進歩

ドラッグデリバリーシステムの技術革新は、新技術のおかげであり、眼科用剤市場の概観を好転させる大きな要因となっています。マイクロエマルション、ナノテクノロジー、眼内挿入物などの新しい製剤の可能性は、より優れた有効性、安全性、患者のアドヒアランスを提供します。例えば、ナノサイズの薬剤キャリアは、標的とする眼組織への薬剤のバイオアベイラビリティを大幅に向上させることができるため、頻繁な投与の必要性や薬剤に伴う副作用を軽減することができます。その結果、市場で競合優位に立つため、こうした技術に投資する企業が増えています。業界では、新規の眼科ドラッグデリバリーシステムの特許数が増加しています。前述の研究開発（R&D）投資はすべて、新しいドラッグデリバリー技術の恩恵を受けるセグメントにおける市場成長の予測に裏打ちされています。このことは、現在の眼科治療のパラダイムを大きく破壊する能力があることを意味しています。

有利な政府の取り組みと資金調達

政府の政策は、眼科用剤市場の見通しを明るくする重要な要因です。世界各国の政府は、効果的な眼科医療をより利用しやすくするなど、ヘルスケア・インフラを改善するためのさまざまなイニシアチブを打ち出しています。例えば、眼科医療センターの開設や開発への助成、新薬開発のための研究投資、眼病に関する情報の普及などの機会を提供している国は数多くあります。米国では、国立眼科研究所が眼科分野の研究に多額の資金を提供しています。これにより、この分野での飛躍的な進歩が促進され、新薬の開発や、視力回復のための産業界におけるチャンスが広がっています。さらに、FDAの画期的治療薬指定などのルートを通じてより早く医薬品が承認されることで、視力回復のための眼科ソリューションの市場参入が促進されます。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界の眼科用剤市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • 処方薬
  • 市販薬

第7章 市場内訳：薬剤クラス別

  • 緑内障予防
  • 感染防止
  • 抗炎症
  • 抗アレルギー
  • その他

第8章 市場内訳：適応症別

  • ドライアイ
  • 緑内障
  • 感染症/炎症/アレルギー
  • 網膜疾患
  • その他

第9章 市場内訳：剤形別

  • 液状点眼薬
  • 固形点眼薬
  • 半固形点眼薬
  • マルチコンパートメントドラッグデリバリーシステム
  • その他

第10章 市場内訳：流通チャネル別

  • 病院薬局
  • ドラッグストア
  • オンライン薬局
  • その他

第11章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第12章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第13章 バリューチェーン分析

第14章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第15章 価格分析

第16章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • Aerie Pharmaceuticals Inc.
    • Akorn Inc.
    • Alcon
    • Bausch Health Companies Inc.
    • Bayer AG
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novartis AG
    • Regeneron Pharmaceuticals Inc.
    • Santen Pharmaceutical Co. Ltd.
    • Sun Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Ophthalmic Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Ophthalmic Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Ophthalmic Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Ophthalmic Drugs Market: Breakup by Type (in %), 2024
  • Figure 5: Global: Ophthalmic Drugs Market: Breakup by Drug Class (in %), 2024
  • Figure 6: Global: Ophthalmic Drugs Market: Breakup by Indication (in %), 2024
  • Figure 7: Global: Ophthalmic Drugs Market: Breakup by Dosage Form (in %), 2024
  • Figure 8: Global: Ophthalmic Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 9: Global: Ophthalmic Drugs Market: Breakup by Region (in %), 2024
  • Figure 10: Global: Ophthalmic Drugs (Prescription Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 11: Global: Ophthalmic Drugs (Prescription Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 12: Global: Ophthalmic Drugs (Over-the-counter Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 13: Global: Ophthalmic Drugs (Over-the-counter Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 14: Global: Ophthalmic Drugs (Anti-glaucoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 15: Global: Ophthalmic Drugs (Anti-glaucoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 16: Global: Ophthalmic Drugs (Anti-infection) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 17: Global: Ophthalmic Drugs (Anti-infection) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 18: Global: Ophthalmic Drugs (Anti-inflammation) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 19: Global: Ophthalmic Drugs (Anti-inflammation) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 20: Global: Ophthalmic Drugs (Anti-allergy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 21: Global: Ophthalmic Drugs (Anti-allergy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 22: Global: Ophthalmic Drugs (Other Drug Classes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 23: Global: Ophthalmic Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 24: Global: Ophthalmic Drugs (Dry Eye) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 25: Global: Ophthalmic Drugs (Dry Eye) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 26: Global: Ophthalmic Drugs (Glaucoma) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 27: Global: Ophthalmic Drugs (Glaucoma) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 28: Global: Ophthalmic Drugs (Infection/Inflammation/Allergy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 29: Global: Ophthalmic Drugs (Infection/Inflammation/Allergy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 30: Global: Ophthalmic Drugs (Retinal Disorders) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 31: Global: Ophthalmic Drugs (Retinal Disorders) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 32: Global: Ophthalmic Drugs (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 33: Global: Ophthalmic Drugs (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 34: Global: Ophthalmic Drugs (Liquid Ophthalmic Drug Forms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 35: Global: Ophthalmic Drugs (Liquid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 36: Global: Ophthalmic Drugs (Solid Ophthalmic Drug Forms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 37: Global: Ophthalmic Drugs (Solid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 38: Global: Ophthalmic Drugs (Semisolid Ophthalmic Drug Forms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 39: Global: Ophthalmic Drugs (Semisolid Ophthalmic Drug Forms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 40: Global: Ophthalmic Drugs (Multicompartment Drug Delivery Systems) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 41: Global: Ophthalmic Drugs (Multicompartment Drug Delivery Systems) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 42: Global: Ophthalmic Drugs (Other Dosage Forms) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 43: Global: Ophthalmic Drugs (Other Dosage Forms) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 44: Global: Ophthalmic Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 45: Global: Ophthalmic Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 46: Global: Ophthalmic Drugs (Drug Stores) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 47: Global: Ophthalmic Drugs (Drug Stores) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 48: Global: Ophthalmic Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 49: Global: Ophthalmic Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 50: Global: Ophthalmic Drugs (Other Distribution Channels) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 51: Global: Ophthalmic Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 52: North America: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 53: North America: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 54: United States: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 55: United States: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 56: Canada: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 57: Canada: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 58: Asia-Pacific: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 59: Asia-Pacific: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 60: China: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 61: China: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 62: Japan: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 63: Japan: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 64: India: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 65: India: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 66: South Korea: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 67: South Korea: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 68: Australia: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 69: Australia: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 70: Indonesia: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 71: Indonesia: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 72: Others: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 73: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 74: Europe: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 75: Europe: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 76: Germany: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 77: Germany: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 78: France: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 79: France: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 80: United Kingdom: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 81: United Kingdom: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 82: Italy: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 83: Italy: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 84: Spain: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 85: Spain: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Russia: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 87: Russia: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 88: Others: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 89: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Latin America: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 91: Latin America: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 92: Brazil: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 93: Brazil: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 94: Mexico: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 95: Mexico: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 96: Others: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 97: Others: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 98: Middle East and Africa: Ophthalmic Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 99: Middle East and Africa: Ophthalmic Drugs Market: Breakup by Country (in %), 2024
  • Figure 100: Middle East and Africa: Ophthalmic Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 101: Global: Ophthalmic Drugs Industry: SWOT Analysis
  • Figure 102: Global: Ophthalmic Drugs Industry: Value Chain Analysis
  • Figure 103: Global: Ophthalmic Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Ophthalmic Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Ophthalmic Drugs Market Forecast: Breakup by Type (in Million USD), 2025-2033
  • Table 3: Global: Ophthalmic Drugs Market Forecast: Breakup by Drug Class (in Million USD), 2025-2033
  • Table 4: Global: Ophthalmic Drugs Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 5: Global: Ophthalmic Drugs Market Forecast: Breakup by Dosage Form (in Million USD), 2025-2033
  • Table 6: Global: Ophthalmic Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 7: Global: Ophthalmic Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 8: Global: Ophthalmic Drugs Market: Competitive Structure
  • Table 9: Global: Ophthalmic Drugs Market: Key Players
目次
Product Code: SR112025A5287

The global ophthalmic drugs market size reached USD 47.2 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 71.2 Billion by 2033, exhibiting a growth rate (CAGR) of 4.44% during 2025-2033. The market is propelled by the rising number of individuals diagnosed with eye diseases, significant technological advancements in drug delivery systems, favorable government initiatives and funding, rising geriatric population, and increasing number of individuals suffering with diabetes.

Ophthalmic Drugs Market Analysis:

Major Market Drivers: The rising issues related to eyes, significant developments in drug formulations, and robust investment in technology and pharmaceutical research sectors are some of the major market drivers driving the ophthalmic drugs growth.

Key Market Trends: The rising number of individuals opting for combination therapies, increasing strategic partnerships among industry players, and the rising emphasis on creating treatments for conditions that were considered untreatable previously are some of the ophthalmic drugs market trends.

Geographical Trends: North America leads the market on account of a strong healthcare infrastructure and the increasing amount of diagnosis of diabetes-related eye conditions. The second largest market of the industry is Europe due to its rising aging population and increasing research and development (R&D) activities across the region.

Competitive Landscape: AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd, are among some of the key players in the ophthalmic drugs industry.

Challenges and Opportunities: Challenges of this market include the strict regulatory environments which lead to a delay in drug approvals and rising cost of developed ophthalmic drugs. Moreover, ophthalmic drugs market recent opportunities include the potential of the emerging markets accredited to the rising healthcare access.

Ophthalmic Drugs Market Trends:

Rising Prevalence of Eye Diseases Among Individuals

The increasing eye-related issues worldwide are majorly escalating the ophthalmic drugs demand. As per the data, illnesses such as cataracts, glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are driving the market. According to the WORLD HEALTH ORGANIZATION (WHO), at least 2.2 Billion individuals each year have a near of distance vision impairment. The report also states that minimum 1 Billion of these cases of vision impairment could have been avoided or is yet to be prevented. The rising number of individuals with eye diseases are significantly leading to a rise in the demand for these therapeutic drugs such as anti-glaucoma medications, anti-VEGF agents, and anti-inflammatory agents. This correlation is supported by numerous market research reports which depict promising advanced treatment solutions and promote ophthalmic drugs market recent development activities.

Significant Technological Advancements in Drug Delivery Systems

The innovation of drug delivery systems, which can be accredited to novel technologies has been a major factor in creating a positive ophthalmic drugs market overview. New formulation possibilities such as microemulsions, nanotechnology, or ocular inserts offer better efficacy, safety, and patient adherence. For instance, drug carriers at a nano-size scale can significantly improve the bioavailability of the drug to the targeted ocular tissues, thereby reducing the need for frequent dosing and any side effects associated with the drug. As a result, more companies are investing in these technologies in order to gain a competitive edge in the market. There is a growing number of novel ophthalmic drug delivery system patents in the industry. All of the aforementioned research and development (R&D) investments are underpinned by the projections of market growth within the segments that benefit from new drug delivery technologies. This implies their ability to significantly disrupt the present ophthalmology treatment paradigm.

Favorable Government Initiatives and Funding

Government policies and act as a vital factor creating a positive ophthalmic drugs market outlook. Governments worldwide have launched various initiatives to improve healthcare infrastructure, including making effective eye care more accessible. For instance, numerous countries provide opportunities for subsidizing the opening and development of eye care centers, investing in research to create new drugs, and spreading information about eye diseases. In the United States, the National Eye Institute provides significant funding for research in the ophthalmic field. This propels a significant breakthrough in this area, opening up new drugs and opportunities in the industry for good vision. Moreover, faster drug approvals through routes such as FDA's Breakthrough Therapy designation improve market entry for visionary ophthalmic solutions.

Ophthalmic Drugs Industry Segmentation:

Breakup by Type:

  • Prescription Drugs
  • Over-the-counter Drugs

Prescription drugs accounts for the majority of the market share

The highest ophthalmic drugs market revenue is deriving from prescription drugs. This can be accredited to the requirement of regulated forms of treatment for certain complex or severe eye disorders. Glaucoma, age-regulated macular degeneration, diabetic retinopathy, and many other conditions are typically treated with prescription medication that must be administered in precise dosages and only used through patient monitoring by a healthcare provider. Age-related macular degeneration can be categorized as dry AMD and wet AMD, and is a primary case of vision loss in individuals 50 years or older. Approximately 80% of individuals (8 out of 10) are diagnosed with dry form AMD. The rapid growth of the patient population proves the irreplaceability of prescription drugs in successful disease treatment and therapy.

Breakup by Drug Class:

  • Anti-glaucoma
  • Anti-infection
  • Anti-inflammation
  • Anti-allergy
  • Others

Anti-glaucoma holds the largest share in the industry

The largest ophthalmic drugs market share is held by anti-glaucoma drugs, where glaucoma is the second leading cause of irreversible blindness globally. According to the NATIONAL INSTITUE OF HEALTH (NIH), the number of individuals suffering with glaucoma globally will rise upto 111.8 million by 2040. A rapidly growing glaucoma patient population signifies that patients need effective therapeutics on a long-term basis in order to maintain visual function, and hence there is significant demand for this segment. Additionally, drug formulation is constantly being developed to achieve maximum relief for glaucoma patients and compliance with the treatment on the part of the patient.

Breakup by Indication:

  • Dry Eye
  • Glaucoma
  • Infection/Inflammation/Allergy
  • Retinal Disorders
  • Others

Retinal disorders represent the leading market segment

Retinal disorders account for a large part of the ophthalmic drugs market, mainly due to the high frequency of diseases and their severity, which includes diabetic retinopathy and age-related macular degeneration. As per a report published by the NATIONAL INSTITUE OF HEALTH (NIH), individuals diagnosed with type 1, type 2, and gestational diabetes are more prone to diabetic retinopathy. The report also suggested that diabetic retinopathy can also lead to other serious eye conditions, such as diabetic macular edema and neovascular glaucoma. With time, approximately 1 in 15 individuals with diabetes develop DME. In the absence of treatment, these diseases often lead to complete blindness and require constant drug support, due to which the consumption of drugs in this segment is significant.

Breakup by Dosage Form:

  • Liquid Ophthalmic Drug Forms
  • Solid Ophthalmic Drug Forms
  • Semisolid Ophthalmic Drug Forms
  • Multicompartment Drug Delivery Systems
  • Others

Liquid ophthalmic drug forms exhibit a clear dominance in the market

On account of the need for easily administered and fast-acting medication directly into the eye, liquid ophthalmic drugs are the largest segment in the market by dosage form. Liquid dosage forms include drops, solutions, tinctures, injections, tinctures, elixirs, and syrups. Considering the relatively wide range of methods for delivering liquid medication into the eye, drops are the most prevalent, offering better controllability of dosage and higher patient adherence, thus impelling the ophthalmic drugs market growth. As per the NATIONAL INSTITUTE OF HEALTH (NIH), demand for liquid ophthalmic formulations is prominently high, with 90% of prescribed medications being eye drops. It is also driven by the introduction of non-preserved and multi-dose packaging, which increases convenience and safety. Thus, liquid formulations are widely preferred by patient and healthcare providers in cases of eye conditions.

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Drug Stores
  • Online Pharmacies
  • Others

Hospital pharmacies dominates the market

In the market breakup by distribution channel, hospital pharmacies currently constitute the largest segment. The factor dictating this is the direct integration of these pharmacies into the healthcare facilities and immediate patient care. As a result, patients have timely access to the ophthalmic medications prescribed by their ophthalmologists. Early treatment of acute and chronic eye conditions is essential to prevent vision impairment and blindness. Hospital pharmacies, in turn, are the first to receive new drug approvals, given their affiliation with manufacturers and the purchasing power. As a result, the drug distribution and administration process are facilitated, patient adherence improves, and outcomes enhance.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

North America leads the market, accounting for the largest ophthalmic drugs market share

The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

North America holds the largest market share due to the developed healthcare system of the region, high healthcare expenditures, and strong presence of big pharma. Moreover, the eye disease rate in the North is high due to glaucoma, for instance, according to the NATIONAL HEALTH INSTITUE (NIH), 3 million individuals in the United States are affected by glaucoma. Another prominent reason is the sponsorship of the United States in medical research, with eye treatment gaining notable financial support.

Competitive Landscape:

The ophthalmic drugs market report has also provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the major market players in the metal fiber industry include AbbVie Inc., Aerie Pharmaceuticals Inc., Akorn Inc., Alcon, Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche AG, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Regeneron Pharmaceuticals Inc., Santen Pharmaceutical Co. Ltd. and Sun Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the ophthalmic drugs market?
  • 2.What is the future outlook of ophthalmic drugs market?
  • 3.What are the key factors driving the ophthalmic drugs market?
  • 4.Which region accounts for the largest ophthalmic drugs market share?
  • 5.Which are the leading companies in the global ophthalmic drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Ophthalmic Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Prescription Drugs
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Over-the-counter Drugs
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Drug Class

  • 7.1 Anti-glaucoma
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Anti-infection
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Anti-inflammation
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Anti-allergy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Others
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Dry Eye
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Glaucoma
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Infection/Inflammation/Allergy
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Retinal Disorders
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by Dosage Form

  • 9.1 Liquid Ophthalmic Drug Forms
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Solid Ophthalmic Drug Forms
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Semisolid Ophthalmic Drug Forms
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Multicompartment Drug Delivery Systems
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast
  • 9.5 Others
    • 9.5.1 Market Trends
    • 9.5.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Drug Stores
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia-Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Analysis

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 AbbVie Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Aerie Pharmaceuticals Inc.
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
    • 16.3.3 Akorn Inc.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
    • 16.3.4 Alcon
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 Financials
    • 16.3.5 Bausch Health Companies Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
    • 16.3.6 Bayer AG
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 F. Hoffmann-La Roche AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 SWOT Analysis
    • 16.3.8 Johnson & Johnson
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 Merck & Co. Inc.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
      • 16.3.9.4 SWOT Analysis
    • 16.3.10 Novartis AG
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Regeneron Pharmaceuticals Inc.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis
    • 16.3.12 Santen Pharmaceutical Co. Ltd.
      • 16.3.12.1 Company Overview
      • 16.3.12.2 Product Portfolio
    • 16.3.13 Sun Pharmaceutical Industries Ltd.
      • 16.3.13.1 Company Overview
      • 16.3.13.2 Product Portfolio